Harvard Bioscience, Inc. revenue by segment HBIO

Harvard Bioscience, Inc. splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Instruments Equipment Software And Accessories at $78.3 million, 90% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
FY 2016
Dec 31, 2016
Revenue
88
87
94
112
113
119
102
116
121
77
105
Instruments Equipment Software And Accessories
79
-2.3%
share 90.1%
78
-10.0%
share 90.4%
87
-17.7%
share 92.4%
106
-2.3%
share 94.2%
108
-5.2%
share 95.4%
114
+17.1%
share 96.0%
97
share 95.5%
—
—
—
—
Service Maintenance And Warranty Contracts
9
+11.9%
share 9.9%
8
+15.6%
share 9.6%
7
+9.7%
share 7.6%
7
+26.4%
share 5.8%
5
+8.0%
share 4.6%
5
+3.5%
share 4.0%
5
share 4.5%
—
—
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Laboratory Analytical Instruments (SIC 3826)
Listed as
HBIO (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Holliston, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1123494

Other Laboratory Analytical Instruments companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.